KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Liabilities (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Total Liabilities for 18 consecutive years, with $4.1 billion as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities fell 1.08% year-over-year to $4.1 billion; the TTM value through Mar 2026 reached $4.1 billion, down 1.08%, while the annual FY2025 figure was $4.2 billion, 0.1% changed from the prior year.
  • Total Liabilities hit $4.1 billion in Q1 2026 for Alnylam Pharmaceuticals, down from $4.2 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $4.6 billion in Q3 2025 and bottomed at $3.0 billion in Q1 2022.
  • Average Total Liabilities over 5 years is $3.9 billion, with a median of $4.0 billion recorded in 2024.
  • Year-over-year, Total Liabilities surged 32.63% in 2022 and then dropped 1.08% in 2026.
  • Alnylam Pharmaceuticals' Total Liabilities stood at $3.7 billion in 2022, then rose by 9.34% to $4.1 billion in 2023, then increased by 3.02% to $4.2 billion in 2024, then increased by 0.1% to $4.2 billion in 2025, then fell by 2.94% to $4.1 billion in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $4.1 billion, $4.2 billion, and $4.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.